Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | dipeptidyl aminopeptidase 1 | 0.0217 | 1 | 1 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.0138 | 0.516 | 1 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0154 | 0.6157 | 0.6157 |
Echinococcus granulosus | cathepsin b | 0.0154 | 0.6157 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0154 | 0.6157 | 1 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0154 | 0.6157 | 0.6157 |
Brugia malayi | cathepsin B-like cysteine proteinase | 0.0154 | 0.6157 | 0.5 |
Echinococcus multilocularis | cathepsin b | 0.0154 | 0.6157 | 0.5 |
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.0088 | 0.2084 | 0.2084 |
Giardia lamblia | Encystation-specific protease | 0.0088 | 0.2084 | 0.2084 |
Toxoplasma gondii | cathepsin CPC1 | 0.0217 | 1 | 1 |
Schistosoma mansoni | dipeptidyl-peptidase I (C01 family) | 0.0217 | 1 | 1 |
Toxoplasma gondii | preprocathepsin c precursor, putative | 0.0217 | 1 | 1 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.0154 | 0.6157 | 1 |
Echinococcus multilocularis | cathepsin b | 0.0154 | 0.6157 | 0.5 |
Plasmodium vivax | dipeptidyl aminopeptidase 1, putative | 0.0217 | 1 | 1 |
Trypanosoma brucei | cysteine peptidase C (CPC) | 0.0054 | 0 | 0.5 |
Echinococcus granulosus | cathepsin b | 0.0154 | 0.6157 | 0.5 |
Plasmodium falciparum | dipeptidyl aminopeptidase 2 | 0.0217 | 1 | 1 |
Leishmania major | cysteine peptidase C (CPC),CPC cysteine peptidase, Clan CA, family C1, Cathepsin B-like | 0.0054 | 0 | 0.5 |
Toxoplasma gondii | cathepsin CPC2 | 0.0088 | 0.2084 | 0.2084 |
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.0154 | 0.6157 | 0.6157 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0154 | 0.6157 | 0.6157 |
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.0088 | 0.2084 | 0.2084 |
Plasmodium vivax | dipeptidyl aminopeptidase 2, putative | 0.0217 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.